Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.82 |
| ▸ | RET | P07949 | 10/20 | 0.82 |
| ▸ | KIF5B | P33176 | 9/20 | 0.82 |
| ▸ | EGFR | P00533 | 10/20 | 0.74 |
| ▸ | JAK3 | P52333 | 2/20 | 0.74 |
| ▸ | CLK1 | P49759 | 2/20 | 0.74 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.74 |
| ▸ | FBP1 | P09467 | 2/20 | 0.74 |
| ▸ | AURKA | O14965 | 1/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.74 |
| ▸ | INSR | P06213 | 1/20 | 0.74 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.74 |
| ▸ | FLT4 | P35916 | 1/20 | 0.74 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.74 |
| ▸ | TEK | Q02763 | 1/20 | 0.74 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.74 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.71 |
| ▸ | FLT1 | P17948 | 2/20 | 0.71 |
| ▸ | GAK | O14976 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7870579 | 0.90 | KDR (1.00) | KDRRETKIF5BEGFRJAK3 | |
| Hydrochloric Acid SCHEMBL7867185 | 0.89 | KDR (0.98) | KDRRETKIF5BEGFRJAK3 | |
| SCHEMBL22590721 | 0.89 | EGFR (0.80) | KDRRETKIF5BEGFRJAK3 | |
| SCHEMBL2100447 | 0.89 | KDR (0.80) | KDRRETKIF5BEGFRCLK1 | |
| SCHEMBL907182 | 0.87 | KDR (0.77) | KDRRETKIF5BEGFRJAK3 | |
| SCHEMBL22630825 | 0.87 | KDR (0.77) | KDRRETKIF5BEGFRJAK3 | |
| SCHEMBL6068633 | 0.86 | KDR (0.82) | KDRRETKIF5BEGFRJAK3 | |
| SCHEMBL6668470 | 0.86 | JAK3 (0.73) | KDRRETKIF5BEGFRJAK3 | |
| SCHEMBL14095961 | 0.85 | EGFR (0.80) | KDRRETKIF5BEGFRJAK3 | |
| SCHEMBL30505605 | 0.85 | EGFR (1.00) | KDREGFRCLK1FBP1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039002-A1 | 6,7-Dimethoxyquinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE | 2004-02-26 | — | — | US | claimed |
| JP-2002540103-A | — | — | 2002-11-26 | — | — | JP | claimed |
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2002-09-26 | — | — | US | claimed |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | PARKER HUGHES INSTITUTE | 2002-08-15 | — | — | US | claimed |
| EP-1163228-A1 | QUINAZOLINES AND THERAPEUTIC USE THEREOF | Parker Hughes Institute (US) | 2001-12-19 | — | — | EP | claimed |
| EP-1162974-A1 | QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF | Parker Hughes Institute (US) | 2001-12-19 | — | — | EP | claimed |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HUGHES INSTITUTE (US) | 2001-08-23 | — | — | US | claimed |
| US-6258820-B1 | ANTITUMOR AGENTS | PARKER HUGHES INSTITUTE | 2001-07-10 | — | — | US | claimed |
| WO-2000056720-A1 | QUINAZOLINES AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | claimed |
| WO-2000056338-A1 | QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | claimed |
| WO-2017040459-A1 | IMPROVED SOLUBILITY FOR TARGET COMPOUNDS | Aunova Medchem LLC (US) | 2017-03-09 | — | — | WO | disclosed |
| US-7038049-B2 | Haloanilino quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050075353-A1 | Quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004013091-A2 | 4-ANILIDO SUBSTITUTED QUINAZOLINES AND USE THEREOF AS INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-02-12 | — | — | WO | disclosed |
| US-6638939-B2 | Anticancer agents | PARKER HUGHES INSTITUTE | 2003-10-28 | — | — | US | disclosed |
| WO-2001035952-A2 | RADIOSENSITIZATION OF HUMAN GLIOBLASTOMA CELLS BY QUINAZOLINE COMPOUNDS | PARKER HUGUES INSTITUTE (US) | 2001-05-25 | — | — | WO | disclosed |
| EP-1100787-A1 | LIPID-LOWERING QUINAZOLINE DERIVATIVE | Parker Hughes Institute (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000056720-A1 | QUINAZOLINES AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000056338-A1 | QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000006554-A1 | LIPID-LOWERING QUINAZOLINE DERIVATIVE | PARKER HUGHES INSTITUTE (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075353-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | KDR 3004/4885RET 1370/4885KIF5B 3899/4885 |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | CMA1, MAST3, MAST1 | KDR 2810/4885RET 2800/4885KIF5B 3284/4885 |
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | KDR 3004/4885RET 1370/4885KIF5B 3899/4885 |
| US-20040039002-A1 | 6,7-Dimethoxyquinazolines and therapeutic use thereof | HRH2, HNMT, HRH4 | KDR 2273/4885RET 1115/4885KIF5B 3041/4885 |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | KDR 3004/4885RET 1370/4885KIF5B 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.